Rapid Resolution of Hyperammonemia in Neonates Using Extracorporeal Membrane Oxygenation as a Platform to Drive Hemodialysis

OBJECTIVE: We aimed to clarify the impact of Extracorporeal Membrane Oxygenation (ECMO) as a platform to drive hemodialysis (HD) for ammonia clearance on outcomes of neonates with severe hyperammonemia. STUDY DESIGN: All neonates treated for hyperammonemia at a single children’s hospital between 1992 and 2016 were identified. Patient characteristics and outcomes were compared between those receiving medical management or ECMO/HD. RESULT: Twenty-five neonates were treated for hyperammonemia, of which 13 (52%) received ECMO/HD. Peak ammonia levels among neonates treated with ECMO/HD were significantly higher than those medically-managed (1041 [IQR 902–1581] μmol/L versus 212 [IQR 110–410] μmol/L; p=0.009). Serum ammonia levels in the ECMO/HD cohort declined to the median of medically managed within 4.5 (IQR 2.9–7.0) hours and normalized within 7.3 (IQR 3.6–13.5) hours. All neonates survived ECMO/HD, and 9 (69.2%) survived to discharge. CONCLUSION: ECMO/HD is an effective adjunct to rapidly clear severe hyperammonemia in newborns, reducing potential neurodevelopmental morbidity.